nipah
viru
biosafeti
level
pathogen
caus
sever
respiratori
ill
enceph
human
identifi
novel
small
molecul
target
nipah
viru
replic
potenti
therapeut
southern
research
institut
galveston
nation
laboratori
jointli
develop
autom
highthroughput
screen
platform
capabl
test
compound
per
day
within
biocontain
use
platform
screen
librari
use
cellbas
highthroughput
screen
compound
inhibit
virusinduc
cytopath
effect
pilot
effort
compound
identifi
ec
valu
rang
lm
select
three
sulfonamid
compound
ec
valu
lm
character
point
intervent
viral
replic
cycl
broad
antivir
efficaci
develop
ht
capabl
contain
chang
paradigm
drug
discoveri
highli
pathogen
agent
platform
readili
modifi
identifi
prophylact
postexposur
therapeut
candid
pathogen
particularli
ebola
marburg
lassa
virus
n
ipah
viru
niv
member
genu
henipaviru
famili
paramyxovirida
caus
sever
respiratori
ill
enceph
human
first
human
case
niv
identifi
outbreak
sever
febril
enceph
malaysia
singapor
outbreak
patient
enceph
report
fatal
primari
mode
transmiss
human
believ
pigtohuman
outbreak
involv
occup
exposur
pig
addit
outbreak
niv
occur
bangladesh
india
almost
annual
recent
bangladesh
outbreak
associ
significantli
higher
case
fatal
rate
addit
higher
preval
respiratori
diseas
observ
outbreak
persontoperson
contact
patient
carri
highest
risk
transmiss
given
lack
effect
therapeut
vaccin
virus
consid
public
health
concern
list
categori
c
prioriti
pathogen
biodefens
research
nation
institut
allergi
infecti
diseas
addit
niv
consid
overlap
select
agent
regul
center
diseas
control
prevent
anim
plant
health
inspect
servic
unit
state
depart
agricultur
drug
discoveri
niv
hamper
requir
work
viru
biosafeti
level
one
studi
use
pseudotyp
assay
surrog
drug
discoveri
howev
assay
focus
primarili
viral
entri
unlik
identifi
compound
inhibit
step
replic
cycl
recent
highthroughput
screen
ht
assay
avail
wildtyp
niv
requir
fixat
plate
document
inactiv
live
viru
remov
plate
subsequ
immunodetect
viru
replic
southern
research
institut
univers
texa
medic
branch
galveston
nation
laboratori
gnl
collabor
establish
ht
platform
wherein
southern
research
institut
provid
ht
expertis
compound
librari
bioinformat
support
gnl
provid
access
biocontain
laboratori
pathogen
pathogen
expertis
southern
research
institut
previous
develop
ht
platform
environ
adapt
broad
rang
highli
pathogen
virus
platform
use
success
identifi
compound
antivir
activ
first
step
develop
therapeut
describ
extens
previou
screen
strategi
ht
assay
platform
design
screen
compound
per
day
biocontain
platform
valid
pilot
screen
compound
enamin
divers
librari
niv
compound
found
activ
primari
screen
confirm
concentr
respons
test
use
cell
toxic
assay
character
use
viral
titer
reduct
timeofaddit
assay
three
sulfonamid
compound
identifi
nivspecif
antivir
activ
low
cell
toxic
knowledg
first
instanc
ht
platform
implement
environ
vero
cell
american
type
cultur
collect
atcc
grown
dulbecco
modifi
eagl
medium
dmem
thermo
scientif
hyclon
logan
ut
supplement
heatinactiv
fetal
bovin
serum
fb
sigma
aldrich
st
loui
mo
co
atmospher
product
viru
ht
assay
iuml
penicillin
mgml
streptomycin
invitrogen
grand
island
ny
ad
media
ht
antivir
cytotox
assay
cell
expand
passag
frozen
dmso
direct
use
screen
niv
malaysia
strain
genbank
kindli
provid
special
pathogen
branch
center
diseas
control
prevent
atlanta
ga
niv
amplifi
vero
cell
viral
titer
determin
plaqu
assay
briefli
confluent
monolay
vero
cell
seed
plate
infect
serial
dilut
viruscontain
cultur
supernat
h
adsorpt
co
inoculum
remov
cell
overlaid
mixtur
one
part
methylcellulos
one
part
minimum
essenti
media
mem
invitrogen
supplement
fb
iuml
penicillin
mgml
streptomycin
plate
incub
day
co
cell
fix
formalin
monolay
stain
crystal
violet
reveal
plaqu
plaqu
count
viru
titer
express
plaqueform
unit
pfu
ml
work
infecti
viru
carri
class
ii
biosafeti
cabinet
condit
gnl
subset
compound
compound
chemic
divers
librari
provid
enamin
ltd
kiev
ukrain
use
ht
assay
valid
compound
solubil
dmso
mgml
stock
concentr
dispens
assay
plate
nl
volum
use
echo
noncontact
liquid
dispens
labcyt
sunnyval
ca
final
compound
concentr
use
primari
screen
mgml
final
dmso
concentr
difficulti
work
contain
requir
simplifi
assay
design
accomplish
prepar
assay
readi
plate
preplat
compound
use
cell
directli
frozen
stock
assay
uninfect
cell
ad
cell
control
well
infect
well
contain
either
test
compound
dmso
control
cell
mix
viru
multipl
infect
moi
immedi
dispens
compound
plate
cell
plate
use
wellmat
noncontact
dispens
thermo
scientif
waltham
assay
plate
corn
catalog
corn
ny
prepar
southern
research
institut
dispens
nl
test
compound
dmso
control
well
use
echo
plate
seal
frozen
ship
gnl
dri
ice
gnl
plate
brought
room
temperatur
centrifug
transport
laboratori
cell
viru
stock
thaw
cell
dilut
cellsml
dispens
plate
dispens
done
use
matrix
noncontact
liquid
handler
thermo
scientif
final
assay
condit
cell
per
well
nl
compound
dmso
mgml
compound
dmso
viru
moi
ml
plate
incub
h
co
incub
cell
viabil
determin
use
viral
reagent
promega
corp
madison
wi
per
manufactur
instruct
plate
read
luminesc
detect
use
envis
plate
reader
perkinelm
wellesley
integr
time
primari
screen
perform
two
set
first
contain
plate
second
set
contain
plate
detail
assay
paramet
shown
tabl
one
hundr
twenti
compound
inhibit
virusinduc
cytopath
effect
cpe
select
confirmatori
assay
concentr
respons
assay
done
determin
effect
concentr
ec
cytotox
concentr
cc
valu
activ
compound
final
tabl
primari
highthroughput
screen
assay
protocol
tabl
step
paramet
valu
descript
screen
concentr
rang
mgml
twofold
serial
dilut
compound
done
final
dmso
concentr
concentr
respons
toxic
assay
perform
use
condit
describ
primari
assay
establish
ec
cc
valu
compound
ad
assay
plate
dmso
use
echo
handl
per
singl
dose
plate
compound
select
index
si
calcul
divid
highest
test
compound
concentr
mg
ml
cytotox
assay
compound
ec
valu
describ
test
compound
toxic
highest
test
concentr
cc
valu
could
calcul
cell
mix
niv
ml
equival
moi
without
individu
test
compound
time
ec
concentr
incub
inoculum
test
compound
h
incub
viral
supernat
collect
titrat
determin
tissu
cultur
infecti
dose
tcid
briefli
ml
viral
supernat
serial
dilut
inocul
onto
vero
cell
monolay
tissu
cultur
plate
cellswel
plate
incub
co
h
cpe
observ
microscop
reduct
tcid
valu
well
contain
test
compound
compar
obtain
parallel
cultur
viru
dmso
vehicl
confluent
monolay
vero
cell
plate
infect
moi
viru
cell
treat
either
compound
time
ec
dmso
control
variou
time
preinfect
postinfect
h
h
min
h
h
h
h
allow
incub
h
afterward
cell
viabil
determin
use
viral
previous
describ
raw
data
import
activitybas
data
manag
softwar
idb
guildford
surrey
unit
kingdom
determin
zfactor
valu
signaltobackground
sb
percent
inhibit
assay
compound
confirmatori
screen
ec
valu
calcul
compound
inhibit
viralinduc
cpe
least
use
idb
xlfit
function
minimum
maximum
b
paramet
set
respect
likewis
cc
valu
determin
compound
show
decreas
cell
viabil
use
logic
statist
calcul
made
follow
c
mean
cell
control
signal
c
standard
deviat
cell
control
signal
v
mean
viru
control
signal
v
standard
deviat
viru
control
signal
sb
fold
increas
c
v
assay
broad
antivir
efficaci
antivir
assay
influenza
strain
respiratori
syncyti
strain
long
dengu
strain
new
guinea
venezuelan
equin
enceph
strain
perform
previous
describ
develop
valid
effici
rapid
vitro
cellbas
assay
semiautom
ht
divers
compound
librari
antivir
efficaci
wildtyp
niv
laboratori
preliminari
assay
develop
done
manual
format
phase
assay
develop
defin
optimum
cell
plate
densiti
viru
moi
assay
durat
done
maxim
signal
window
retain
sensit
measur
endpoint
detect
method
measur
observ
virusinduc
cpe
measur
viabil
nivinfect
cell
cell
cultur
employ
commerci
avail
viral
toxglo
luminesc
cell
viabil
kit
determin
cell
viabil
base
quantif
atp
indic
metabol
activ
cell
procedur
involv
ad
singl
reagent
combin
deterg
luciferas
substrat
directli
previous
cultur
cell
media
lyse
cell
produc
bioluminesc
signal
proport
amount
atp
present
caveat
compound
inhibit
luciferas
niv
replic
inher
give
neg
signal
optim
assay
sensit
compound
may
affect
viru
replic
use
viru
moi
reproduc
caus
cpe
vero
cell
endpoint
h
base
previou
screen
studi
virus
chose
moi
allow
multipl
cycl
viral
replic
low
moi
also
allow
us
identifi
compound
inhibit
stage
viru
life
cycl
preliminari
assay
develop
assay
adapt
micropl
format
criteria
success
adapt
mean
cv
posit
cell
control
less
sb
minim
plate
pattern
bia
assay
paramet
optim
assay
valid
run
least
two
z
plate
three
separ
day
data
z
plate
use
evalu
coeffici
variat
cv
zfactor
sb
plate
well
bia
liquid
handl
effect
reagent
stabil
endpoint
stabil
also
evalu
final
step
valid
pilot
screen
compound
librari
follow
dose
respons
confirm
toxic
test
activ
compound
final
step
valid
ht
assay
niv
pilot
screen
small
molecul
librari
contain
compound
singledos
format
follow
dose
respons
confirm
singl
dose
pilot
screen
assay
plate
contain
control
well
compound
total
compound
screen
figur
show
graph
characterist
screen
result
minim
hit
criteria
screen
defin
three
time
standard
deviat
percent
inhibit
compound
well
low
statist
cutoff
indic
extrem
robust
assay
howev
use
inhibit
hit
cutoff
observ
hit
rate
compound
screen
inhibit
virusinduc
cpe
greater
shade
gray
fig
rel
luminesc
valu
median
cell
viru
control
use
calcul
percent
cell
viabil
percent
inhibit
cpe
sb
shown
fig
seen
figur
niv
antivir
primari
assay
broad
signal
window
low
platetopl
standard
deviat
excel
reproduc
zfactor
valu
plate
shown
fig
assay
produc
z
valu
consid
suitabl
ht
zfactor
provid
quantit
mean
measur
suitabl
particular
assay
use
larg
ht
defin
mean
valu
standard
deviat
posit
neg
control
figur
primari
assay
low
standard
deviat
control
larg
signal
window
contribut
mean
zfactor
equat
separ
standard
deviat
mean
control
indic
assay
robust
enough
expect
predict
singlerepl
screen
lastli
primari
screen
perform
two
set
differ
day
slight
variat
median
control
valu
zfactor
observ
set
set
fig
notabl
control
valu
reduc
proport
reduct
absolut
luminesc
signal
could
caus
number
factor
like
due
either
slightli
fewer
cell
well
set
slightli
lower
ambient
temperatur
endpoint
reagent
read
set
concentr
respons
assay
perform
tabl
show
zfactor
valu
sb
hit
rate
cv
valu
confirm
rate
hit
compound
inhibit
cpe
confirm
rate
indic
primari
ht
assay
accur
identifi
compound
effect
reduc
viralinduc
cell
death
assess
potenti
toxic
compound
cytotox
assay
perform
parallel
compound
select
determin
select
criteria
compound
valu
pilot
screen
use
calcul
mean
tabl
shown
assay
produc
z
valu
consid
suitabl
ht
primari
screen
perform
two
set
first
set
contain
plate
second
set
contain
plate
b
c
data
differ
set
primari
screen
indic
shade
label
character
requir
compound
ec
mm
si
base
ec
select
valu
hit
nine
compound
repurchas
dri
powder
retest
duplic
concentr
respons
antivir
toxic
assay
three
compound
met
criteria
select
addit
character
use
timeofaddit
viru
titer
reduct
antivir
assay
broad
efficaci
three
potent
hit
compound
evalu
manual
micropl
format
cpe
cytotox
assay
also
test
viru
titer
reduct
assay
broad
spectrum
antivir
activ
panel
virus
cpebas
assay
niv
confirm
compound
promis
antinipah
activ
ec
valu
mm
si
mm
si
mm
si
figur
list
compound
structur
ec
si
valu
next
viru
titer
reduct
assay
perform
evalu
impact
compound
product
infecti
viral
progeni
follow
incub
rel
titer
progeni
virus
compar
titrat
cpe
assay
compound
effect
inhibit
replic
niv
reduct
titer
rang
compar
control
without
compound
figur
identifi
stage
niv
replic
cycl
compound
interven
perform
parallel
time
addit
experi
triplic
three
hit
compound
data
shown
addit
compound
h
postinfect
show
similar
level
activ
ad
time
simultan
infect
compound
perform
similar
profil
evalu
broadspectrum
antivir
activ
test
three
compound
virus
differ
famili
includ
influenza
viru
strain
famili
orthomyxovirida
respiratori
syncyti
viru
strain
long
famili
paramyxovirida
dengu
viru
strain
new
guinea
famili
flavivirida
venezuelan
equin
enceph
viru
strain
famili
togavirida
ebola
viru
zair
strain
famili
filovirida
doserespons
cellbas
assay
data
shown
antivir
activ
observ
virus
suggest
hit
compound
show
specif
activ
niv
perhap
close
relat
henipavirus
studi
valid
laboratori
ht
platform
discoveri
novel
antivir
compound
niv
use
platform
identifi
three
sulfonamid
compound
inhibit
nivinduc
cpe
viru
replic
ec
valu
mm
select
rang
timeofaddit
experi
show
three
compound
inhibit
niv
infect
ad
h
postinfect
suggest
compound
target
later
stage
viru
replic
rather
earlier
entri
stage
sinc
compound
perform
similar
profil
also
suggest
inhibitori
mechan
compound
may
similar
previou
drug
discoveri
search
niv
antivir
focus
synthesi
novel
fusion
inhibitor
deriv
compound
shown
effect
paramyxovirus
ie
measl
viru
compound
studi
demonstr
ec
valu
rang
mm
si
valu
rang
howev
valu
base
inhibit
function
individu
express
niv
g
f
protein
compound
test
use
viru
infect
assay
sulfonamid
compound
report
demonstr
rang
efficaci
greater
select
viru
infect
therefor
ht
platform
provid
reliabl
rapid
much
need
mean
screen
small
molecul
librari
broad
efficaci
wildtyp
niv
replic
mani
antivir
drug
discoveri
effort
begin
ht
campaign
pathogen
target
interest
howev
limit
report
ht
assay
biocontain
tradit
method
monitor
viru
replic
effect
antivir
compound
includ
either
qualit
visual
observ
cpe
quantiz
infecti
viru
particl
use
plaqu
assay
quantiz
viral
rna
transcript
lowthroughput
realtim
reversetranscriptas
polymeras
chain
reaction
none
method
amen
ht
circumv
challeng
mani
current
ht
effort
use
virus
includ
nipah
ebola
virus
employ
pseudotyp
surrog
recombinantli
attenu
pathogen
downgrad
use
lower
biocontain
level
howev
major
drawback
use
artifici
system
may
accur
repres
respons
fulli
virul
pathogen
compound
term
biolog
biochem
characterist
furthermor
stage
viru
replic
cycl
repres
system
util
sever
limit
assay
address
number
aforement
problem
assay
adapt
valid
high
biocontain
facil
make
possibl
screen
larg
compound
librari
directli
wildtyp
virus
environ
capabl
util
wildtyp
virus
instead
surrog
reduc
time
requir
effect
drug
develop
furthermor
cpebas
ht
assay
allow
evalu
antivir
efficaci
entir
viral
life
cycl
report
valid
htsadapt
assay
specif
niv
result
drug
discoveri
niv
hamper
recent
high
ht
assay
avail
niv
requir
fixat
plate
remov
plate
subsequ
immunodetect
viru
replic
recent
effort
made
adapt
immunoplaqu
assay
microtit
plate
format
util
twostep
assay
protocol
involv
overnight
viru
inocul
vero
cell
monolay
follow
cell
fixat
viru
inactiv
plate
decontamin
transfer
laboratori
immunodetect
assay
perform
howev
number
manipul
safe
regul
transfer
microtit
plate
make
method
impract
autom
ht
antivir
ht
assay
niv
simpl
onestep
protocol
use
flexibl
stabl
luminesc
signal
gener
amount
atp
posit
correl
cellular
viabil
sampl
furthermor
sb
valu
greater
consid
adequ
detect
window
zvalu
greater
consid
robust
enough
ht
assay
zvalu
assay
sb
ratio
suggest
robust
enough
identifi
antivir
compound
singl
dose
singl
replic
ht
assay
howev
hit
rate
similar
report
ht
antivir
assay
lower
confirm
rate
assay
due
concentrationdepend
cytotox
hit
compound
remov
consider
hit
cytotox
characterist
compound
enamin
divers
set
cell
type
use
primari
confirmatori
assay
inher
problem
assay
design
studi
identifi
three
sulfonamid
compound
inhibit
nivinduc
cpe
ec
valu
less
mm
reduc
product
infecti
progeni
viru
timeofaddit
experi
show
three
compound
inhibit
niv
infect
h
postinfect
suggest
compound
target
viru
late
stage
viru
replic
rather
earli
entri
later
stage
assembl
sinc
compound
structur
similar
perform
similar
profil
also
suggest
inhibitori
mechan
compound
may
similar
perform
search
pubchem
three
hit
compound
assess
whether
identifi
hit
bioassay
compound
pubchem
cid
pubchem
cid
found
databas
compound
identifi
hit
bioassay
indic
promiscu
suggest
specif
niv
possibl
henipavirus
although
analog
compound
also
found
pubchem
inform
bioassay
perform
exact
compound
avail
futur
studi
includ
determin
molecular
mechan
niv
inhibit
test
compound
vivo
efficaci
summari
southern
research
institut
collabor
gnl
success
implement
ht
platform
contain
use
niv
viru
prototyp
viru
platform
allow
us
screen
wildtyp
viru
strain
instead
pseudotyp
surrog
recombinantli
attenu
virus
downgrad
use
lower
biocontain
level
throughput
ht
assay
consider
greater
previou
report
ht
use
pathogen
allow
screen
compound
small
molecul
librari
singl
dose
per
day
hit
compound
concentrationdepend
dose
respons
per
day
dual
threat
emerg
pathogen
exhibit
high
mobid
mortal
possibl
pathogen
use
bioterorist
weapon
make
develop
antivir
therapi
increasingli
critic
need
develop
ht
technolog
address
provid
crucial
need
tool
modern
drug
develop
highli
pathogen
virus
